Filing Details
- Accession Number:
- 0001439222-24-000008
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-09 16:26:55
- Reporting Period:
- 2024-01-05
- Accepted Time:
- 2024-01-09 16:26:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1439222 | Agios Pharmaceuticals Inc. | AGIO | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1405288 | A Jacqualyn Fouse | C/O Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-01-05 | 17,500 | $0.00 | 124,466 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-01-09 | 8,391 | $22.99 | 116,075 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Performance share units | Disposition | 2024-01-05 | 17,500 | $0.00 | 17,500 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | M | Direct |
Footnotes
- Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated February 10, 2021.
- Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- The PSUs were granted on February 10, 2021. The PSUs vest upon the achievement of a specified clinical milestone. The performance criteria for the specified clinical milestone was determined to have been met on January 5, 2024, resulting in the vesting of the PSUs. Vested shares will be delivered to the reporting person within three business days after such shares become vested.